PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs
Files
Publication date
2015-09-29
Authors
Prahallad, Anirudh
Heynen, Guus J J E
Germano, Giovanni
Willems, Stefan
Evers, Bastiaan
Vecchione, Loredana
Gambino, Valentina
Lieftink, Cor
Beijersbergen, Roderick L
Di Nicolantonio, Federica
Editors
Advisors
Supervisors
Document Type
Article
Metadata
Show full item recordCollections
License
Abstract
Most BRAF (V600E) mutant melanomas are sensitive to selective BRAF inhibitors, but BRAF mutant colon cancers are intrinsically resistant to these drugs because of feedback activation of EGFR. We performed an RNA-interference-based genetic screen in BRAF mutant colon cancer cells to search for phosphatases whose knockdown induces sensitivity to BRAF inhibition. We found that suppression of protein tyrosine phosphatase non-receptor type 11 (PTPN11) confers sensitivity to BRAF inhibitors in colon cancer. Mechanistically, we found that inhibition of PTPN11 blocks signaling from receptor tyrosine kinases (RTKs) to the RAS-MEK-ERK pathway. PTPN11 suppression is lethal to cells that are driven by activated RTKs and prevents acquired resistance to targeted cancer drugs that results from RTK activation. Our findings identify PTPN11 as a drug target to combat both intrinsic and acquired resistance to several targeted cancer drugs. Moreover, activated PTPN11 can serve as a biomarker of drug resistance resulting from RTK activation.
Keywords
Journal Article, Research Support, Non-U.S. Gov't
Citation
Prahallad, A, Heynen, G J J E, Germano, G, Willems, S M, Evers, B, Vecchione, L, Gambino, V, Lieftink, C, Beijersbergen, R L, Di Nicolantonio, F, Bardelli, A & Bernards, R 2015, 'PTPN11 Is a Central Node in Intrinsic and Acquired Resistance to Targeted Cancer Drugs', Cell Reports [E], vol. 12, no. 12, pp. 1978-85. https://doi.org/10.1016/j.celrep.2015.08.037